

Hemochromatosis and HIV: Unraveling Genetic Susceptibility

*Emmanuel Ifeanyi Obeagu¹ and D.C. Nwosu²

¹Department of Medical Laboratory Science, Kampala International University, Uganda

²Department of Medical Laboratory Science, Imo State University, Owerri, Imo State, Nigeria.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

Hemochromatosis, a disorder characterized by excessive iron absorption leading to systemic iron overload, and Human Immunodeficiency Virus (HIV), a viral infection targeting the immune system, represent significant health challenges worldwide. Concurrently, host genetic factors play a pivotal role in determining susceptibility to HIV infection and disease progression. Genetic polymorphisms affecting immune response pathways, viral entry receptors, and cytokine signaling pathways influence individual susceptibility and disease outcomes. Importantly, population-specific genetic variations contribute to differential HIV susceptibility and response to antiretroviral therapy, emphasizing the need for personalized approaches in HIV management. The intersection of hemochromatosis and HIV introduces unique challenges and clinical implications. Individuals with hemochromatosis may exhibit increased susceptibility to HIV infection due to dysregulated iron metabolism compromising immune function. Conversely, HIV infection can exacerbate iron dysregulation, leading to accelerated progression of hepatic and systemic complications in co-infected individuals. Understanding the intricate interplay between iron homeostasis, immune response, and viral pathogenesis is essential for optimizing therapeutic strategies and improving clinical outcomes in this vulnerable population. Unraveling the genetic susceptibility to hemochromatosis and HIV opens avenues for targeted interventions and preventive measures. Mechanistic insights into the complex interactions between iron metabolism and viral infection may inform the development of novel therapeutic approaches, including iron chelation therapy and immunomodulatory interventions, to mitigate the adverse effects of co-infection.

Keywords: Hemochromatosis, HIV, Genetic Susceptibility, Iron Overload, Immune Response, Co-infection

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. Elite Journal of Medicine, 2024; 2(5): 36-52

Introduction

Hemochromatosis and HIV represent two distinct yet interconnected realms of medical science, each posing significant health challenges globally. Hemochromatosis, a hereditary iron overload disorder, arises from dysregulated iron absorption leading to excessive iron deposition in various organs, predominantly the liver, heart, and pancreas. This condition, if left untreated, can culminate in severe complications such as cirrhosis, cardiomyopathy, and endocrine dysfunction. Conversely, HIV, the causative agent of acquired immunodeficiency syndrome (AIDS), targets the immune system, progressively compromising its function and rendering individuals susceptible to opportunistic infections and malignancies. Despite advancements in treatment, HIV/AIDS remains a major public health concern, particularly in resource-limited settings. While traditionally viewed as disparate entities, recent research has unveiled intriguing connections between hemochromatosis and HIV, suggesting a complex interplay between genetic susceptibility factors, iron metabolism, and immune response. The genetic basis of hemochromatosis primarily revolves around mutations in the HFE gene, particularly the C282Y and H63D variants, which disrupt iron homeostasis by impairing hepcidin regulation and increasing iron absorption. However, emerging evidence indicates that other genes involved in iron metabolism, such as HAMP, TFR2, and SLC40A1, also contribute to the phenotypic expression and variability of hemochromatosis, underscoring the multifaceted nature of this disorder.¹⁻²⁶

Concurrently, host genetic factors play a pivotal role in determining susceptibility to HIV infection and disease progression. Polymorphisms in genes encoding chemokine receptors (e.g., CCR5) and human leukocyte antigens (HLAs) influence viral entry, immune activation, and disease outcome. Moreover, genetic variations in innate and adaptive immune response pathways, including cytokine signaling and T-cell receptor diversity, modulate individual susceptibility to HIV infection and progression to AIDS. Ethnic and population-specific differences in genetic susceptibility further underscore the intricate interplay between host genetics and viral pathogenesis. The intersection of hemochromatosis and HIV introduces unique challenges and clinical implications. Individuals with hemochromatosis may exhibit increased susceptibility to HIV infection due to compromised immune function secondary to iron overload. Conversely, HIV infection can exacerbate iron dysregulation, leading to accelerated progression of hepatic fibrosis, cardiomyopathy, and other systemic complications in co-infected individuals. The synergistic effects of iron overload and immune dysfunction in the context of HIV infection highlight the need for tailored management strategies to address the dual burden of these conditions effectively. Understanding the genetic susceptibility to hemochromatosis and HIV is paramount for elucidating disease pathogenesis, identifying at-risk individuals, and optimizing therapeutic interventions. Genetic screening and counseling may facilitate early detection of hereditary hemochromatosis, enabling timely intervention with phlebotomy or iron chelation therapy to prevent complications. Similarly, insights into host genetic determinants of HIV susceptibility and disease progression may inform the development of personalized treatment regimens and preventive measures, including pre-exposure prophylaxis (PrEP) and immune-based therapies. This review aims to synthesize current knowledge on the genetic underpinnings of hemochromatosis and HIV,

shedding light on their complex interrelationships and potential implications for clinical practice and public health initiatives.²⁷⁻⁵⁶

Genetic Basis of Hemochromatosis

The genetic basis of hemochromatosis lies primarily in mutations affecting genes involved in iron metabolism regulation, particularly the HFE gene located on chromosome 6. The most common mutations associated with hereditary hemochromatosis are the C282Y and H63D variants within the HFE gene. These mutations disrupt the normal function of the HFE protein, which plays a crucial role in regulating iron absorption by interacting with the transferrin receptor and hepcidin, a key regulator of iron homeostasis. The C282Y mutation, occurring in approximately 80-90% of individuals with hereditary hemochromatosis, leads to a defective HFE protein that fails to properly interact with transferrin receptor 1 (TfR1) on the surface of intestinal epithelial cells. As a result, there is a diminished inhibition of intestinal iron absorption, leading to increased iron uptake from the diet and subsequent iron overload in tissues. The H63D mutation, although less common and typically milder in its effects, may also contribute to disruptions in iron homeostasis when present in combination with other genetic or environmental factors. In addition to HFE mutations, other genes have been implicated in the pathogenesis of hemochromatosis. Mutations in genes such as HAMP (encoding hepcidin), TFR2 (encoding transferrin receptor 2), and SLC40A1 (encoding ferroportin) can disrupt iron sensing, trafficking, and export mechanisms, leading to dysregulated iron metabolism and subsequent iron overload. These non-HFE mutations are less common but can contribute to the phenotypic variability observed in individuals with hemochromatosis. Moreover, the penetrance and expressivity of hemochromatosis-associated mutations can be influenced by additional genetic modifiers and environmental factors. Modifier genes involved in iron metabolism, inflammation, and oxidative stress pathways may modulate the clinical phenotype of hemochromatosis, contributing to variations in disease severity and age of onset among affected individuals. Environmental factors such as dietary iron intake, alcohol consumption, and comorbidities (e.g., viral hepatitis) can also influence the progression and clinical manifestations of hemochromatosis in genetically susceptible individuals.⁵⁷⁻⁶⁰

Genetic Factors in HIV Susceptibility

Genetic factors play a critical role in determining susceptibility to Human Immunodeficiency Virus (HIV) infection and influencing disease progression. Host genetic variations can influence various aspects of HIV pathogenesis, including viral entry, immune response, and disease outcome. Key genetic factors implicated in HIV susceptibility include polymorphisms in genes encoding chemokine receptors, human leukocyte antigens (HLAs), and innate and adaptive immune response pathways. One of the most well-studied genetic factors influencing HIV susceptibility is the $\Delta 32$ deletion in the CCR5 gene, which encodes the C-C chemokine receptor type 5. Individuals homozygous for the $\Delta 32$ deletion are resistant to infection by certain strains of HIV, as the absence of functional CCR5 receptors impairs viral entry into target cells, particularly CD4⁺ T lymphocytes and macrophages. Heterozygous carriers of the $\Delta 32$ deletion may exhibit delayed disease progression, highlighting the protective effect of CCR5 deficiency against HIV infection. Human leukocyte antigens (HLAs), encoded by the major histocompatibility complex

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

(MHC) genes, play a crucial role in immune recognition and response. Polymorphisms in HLA genes can influence the presentation of viral antigens to T cells and the subsequent immune response against HIV. Certain HLA alleles have been associated with differential susceptibility to HIV infection and disease progression. For example, *HLA-B57* and *HLA-B27* alleles are associated with slower disease progression and lower viral loads, whereas other alleles, such as *HLA-B*35*, are linked to rapid disease progression.⁶¹⁻⁸¹

In addition to chemokine receptors and HLAs, genetic variations in innate and adaptive immune response pathways can impact HIV susceptibility and disease progression. Polymorphisms in genes encoding components of the innate immune system, such as toll-like receptors (TLRs) and cytokines, can affect the initial immune response to HIV infection. Similarly, genetic variations in genes involved in adaptive immunity, including T-cell receptor (TCR) genes and cytokine signaling pathways, can influence viral replication, immune activation, and disease outcome. Ethnic and population-specific differences in genetic susceptibility to HIV further underscore the complex interplay between host genetics and viral pathogenesis. Certain genetic variants associated with HIV susceptibility and disease progression may be more prevalent in specific populations, contributing to disparities in HIV prevalence and clinical outcomes observed globally. Understanding the genetic determinants of HIV susceptibility and disease progression is essential for developing targeted interventions, including vaccines, antiretroviral therapy, and immune-based therapies, tailored to individual genetic profiles. Moreover, genetic screening and counseling may facilitate personalized approaches to HIV prevention and treatment, ultimately contributing to more effective management of the HIV/AIDS pandemic.⁸²⁻¹⁰¹

Intersection of Hemochromatosis and HIV

The intersection of hemochromatosis and HIV represents a complex interplay between iron metabolism dysregulation and viral pathogenesis, posing unique challenges and clinical implications for affected individuals. Individuals with hemochromatosis may exhibit increased susceptibility to HIV infection due to compromised immune function secondary to iron overload. Iron is essential for the proliferation and virulence of many pathogens, including HIV, and excess iron accumulation in tissues may create a favorable environment for viral replication and dissemination. Moreover, iron overload can impair the function of immune cells, including T lymphocytes and macrophages, compromising their ability to mount an effective antiviral response against HIV. Conversely, HIV infection can exacerbate iron dysregulation in co-infected individuals, leading to accelerated progression of hepatic fibrosis, cardiomyopathy, and other systemic complications associated with hemochromatosis. HIV-associated immune activation and inflammation may further exacerbate iron-mediated tissue damage, contributing to the development of severe complications in co-infected individuals. Additionally, chronic inflammation associated with HIV infection can disrupt hepcidin regulation, leading to alterations in iron metabolism and exacerbating iron overload in susceptible individuals with hemochromatosis.¹⁰²⁻¹²¹

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

The dual burden of hemochromatosis and HIV presents unique challenges in clinical management and therapeutic decision-making. Traditional therapeutic approaches for hemochromatosis, such as phlebotomy or iron chelation therapy, may need to be carefully tailored in co-infected individuals to minimize the risk of exacerbating HIV-related complications or interfering with antiretroviral therapy. Moreover, monitoring of iron parameters and liver function in co-infected individuals is essential to detect and manage complications such as hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. The synergistic effects of iron overload and immune dysfunction in the context of HIV infection underscore the importance of interdisciplinary collaboration in optimizing clinical care for co-infected individuals. Integrated management strategies that address both iron metabolism dysregulation and HIV-related immune dysfunction may improve clinical outcomes and quality of life in this vulnerable population. Moreover, research efforts aimed at elucidating the underlying mechanisms driving the interaction between hemochromatosis and HIV may identify novel therapeutic targets and interventions for mitigating the adverse effects of co-infection.¹²²⁻¹⁴¹

Mechanistic Insights and Future Directions

The interplay between hemochromatosis and HIV involves intricate mechanisms encompassing iron metabolism dysregulation, immune activation, and viral pathogenesis. Iron, an essential nutrient for both host and pathogen, plays a multifaceted role in HIV infection. Excess iron accumulation in tissues, characteristic of hemochromatosis, creates a conducive environment for viral replication and dissemination, potentially exacerbating HIV-related complications. Moreover, iron overload impairs the function of immune cells, compromising their ability to mount an effective antiviral response against HIV. Conversely, HIV infection induces systemic immune activation and inflammation, which can disrupt iron homeostasis by altering hepcidin regulation and promoting iron sequestration within macrophages. This dysregulated iron metabolism may contribute to the progression of hepatic fibrosis, cardiomyopathy, and other complications associated with hemochromatosis. Furthermore, HIV-associated immune dysfunction may impair the clearance of iron-loaded macrophages, exacerbating tissue damage and organ dysfunction in co-infected individuals.¹⁴²⁻¹⁵⁵

Further elucidating the mechanistic underpinnings of the interaction between hemochromatosis and HIV is essential for developing targeted therapeutic interventions and preventive strategies. High-throughput omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, can provide comprehensive insights into the molecular pathways involved in co-infection. Integrative analyses of host genetic factors, viral dynamics, and immune response profiles may uncover novel biomarkers of disease progression and therapeutic targets. Additionally, preclinical models, including cell culture systems and animal models of co-infection, can be employed to dissect the complex interplay between iron metabolism dysregulation and HIV pathogenesis. These models enable the evaluation of potential therapeutic interventions, such as iron chelation therapy, immunomodulatory agents, and combination antiretroviral therapy, in mitigating the adverse effects of co-infection on organ function and clinical outcomes. In the clinical setting, prospective cohort studies and clinical trials are needed to assess the efficacy and safety of tailored management strategies for co-infected individuals. Personalized approaches that

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

account for individual genetic profiles, viral characteristics, and disease stage may optimize treatment outcomes and improve long-term prognosis. Moreover, integrated care models that involve multidisciplinary teams of clinicians, researchers, and allied health professionals are essential for providing comprehensive care and support to co-infected individuals.¹⁵⁶⁻¹⁵⁷

Conclusion

The intersection of hemochromatosis and HIV represents a complex interplay between iron metabolism dysregulation and viral pathogenesis, posing unique challenges and clinical implications for affected individuals. Hemochromatosis, characterized by excessive iron accumulation in tissues, creates a conducive environment for HIV replication and dissemination, potentially exacerbating HIV-related complications. Conversely, HIV infection induces immune activation and inflammation, which can further disrupt iron homeostasis and exacerbate tissue damage in individuals with hemochromatosis. High-throughput omics approaches, preclinical models, and clinical studies provide valuable insights into the molecular pathways involved and guide the development of personalized management strategies for co-infected individuals. Integrated care models involving multidisciplinary teams of clinicians, researchers, and allied health professionals are essential for providing comprehensive care and support to co-infected individuals.

References

1. Özdemir V. Public health in the age of genomics, 'Big Data' and massively collaborative global science. In *Routledge Handbook of Global Public Health in Asia 2014*: 74-90. Routledge.
2. Hinote BP, Wasserman JA. Social and behavioral science for health professionals. Rowman & Littlefield Publishers; 2019.
3. Pietrangelo A. Iron and the liver. *Liver international*. 2016 Jan; 36:116-23.
4. Daniłowicz-Szymanowicz L, Świąteczak M, Sikorska K, Starzyński RR, Raczak A, Lipiński P. Pathogenesis, diagnosis, and clinical implications of hereditary hemochromatosis—the cardiological point of view. *Diagnostics*. 2021;11(7):1279.
5. Siddique A, Kowdley KV. The iron overload syndromes. *Alimentary pharmacology & therapeutics*. 2012 Apr;35(8):876-93.
6. Lal A. Iron in health and disease: an update. *The Indian Journal of Pediatrics*. 2020;87(1):58-65.
7. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. *Annual Review of Physiology*. 2002;64(1):663-80.
8. Pantopoulos K. Inherited disorders of iron overload. *Frontiers in nutrition*. 2018; 5:103.
9. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2002;282(3): G403-14.
10. Anderson GJ, Bardou-Jacquet E. Revisiting hemochromatosis: genetic vs. phenotypic manifestations. *Annals of translational medicine*. 2021;9(8).

11. Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK. Clinical perspectives on hereditary hemochromatosis. *Critical reviews in clinical laboratory sciences*. 2008;45(5):451-84.
12. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
13. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
14. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
15. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
16. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
17. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
18. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
19. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
20. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
21. Obeagu EI, Eze VU, Alaebho EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
22. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.
[https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

23. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
24. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.iosrjournals.org/ViewArticle.aspx?doi=5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf)
25. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-119.
26. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.iosrjournals.org/ViewArticle.aspx?doi=5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).
27. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu Emmanuel Ifeanyi3 et al.IJC RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
28. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.iosrjournals.org/ViewArticle.aspx?doi=5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
29. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](https://doi.org/10.22192/ijcrms.2017.03.02.005)
30. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
31. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://www.iosrjournals.org/ViewArticle.aspx?doi=645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.*

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

- 2022;2(3):128-134.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
33. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022;29-34.
 34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
 35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015).
 36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
 37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
 38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
 39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
 40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-183.DOI: DOI: 10.32474/JCCM.2020.02.000137 [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137).
 41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

- Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
42. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-211.
<http://research.sdpublishers.net/id/eprint/2819/>.
 43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
 44. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
 45. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
 46. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.
<links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf>.
 47. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
 48. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)
<links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf>.
 49. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) <links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf>.
 50. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2016;2(4):29-33. <links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf>.
 51. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci*. 2015;4(4):906-910.

https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.

52. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
53. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
54. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
55. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharmacy Research.* 2014; 391:186-189.
56. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
57. Anderson GJ, Powell LW. HFE and non-HFE hemochromatosis. *International journal of hematology.* 2002; 76:203-207.
58. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. *Annual Review of Physiology.* 2002;64(1):663-680.
59. Nelson JE, Kowdley KV. Non-HFE hemochromatosis: genetics, pathogenesis, and clinical management. *Current gastroenterology reports.* 2005; 7(1):71-80.
60. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. *American journal of hematology.* 2006;81(3):202-209.
61. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
62. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanne CA, Nwanjo HU, Amadike JN, Ezemima MC, Okpomesine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
63. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
64. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.

65. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
66. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
67. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
68. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
69. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
70. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
71. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore).* 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
72. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
73. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
74. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
75. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health.* 2024;2(1):8-22.
76. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology.* 2024;2(1):14-33.
77. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine.* 2024;103(9): e37354.
78. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology.* 2024;2(1):1-3.
79. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology.* 2024;2(1):34-46.

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

80. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
81. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
82. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>;12(01)*.
83. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
84. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;12(01)*.
85. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
86. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
87. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
88. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
89. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
90. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
91. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
92. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
93. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
94. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
95. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
96. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
97. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.

98. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: <http://www.journalijar.com>;12(01).
99. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):38-58.
100. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024;2(3):14-26.
101. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health. 2024;2(1):52-63.
102. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
103. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.
104. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
105. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science. 2024;2(3):59-72.
106. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
107. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
108. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
109. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV. 2024;2(2):60-73.
110. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.
111. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science. 2024;2(2):33-46.
112. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
113. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
114. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology. 2024;2(3):33-44.

Citation: Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. Elite Journal of Medicine, 2024; 2(5): 36-52

115. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
116. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page*: <http://www.journalijar.com>;12(01).
117. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page*: <http://www.journalijar.com>;12(01).
118. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
119. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
120. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.
121. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
122. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
123. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
124. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
125. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.
126. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
127. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
128. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
129. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
130. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
131. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.
132. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.

133. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
134. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
135. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
136. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):42-60.
137. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-105.
138. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*, 2024; 2 (3):25-41.
139. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
140. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
141. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*. 2024;2(3):23-35.
142. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine*. 2024;103(2):e36937.
143. Mitterstiller AM, von Raffay L, Nairz M. Iron Deficiency, Anemia, and the Immune System. In *Nutritional Anemia 2022* Dec 16 (pp. 235-248). Cham: Springer International Publishing.
144. Ganesh GV, Mohanram RK. Metabolic reprogramming and immune regulation in viral diseases. *Reviews in medical virology*. 2022;32(2): e2268.
145. Obeagu EI, Obeagu GU. Exploration of Intricate Relationship between GATA-1 and Anemia in HIV. *Elite Journal of Haematology*, 2024; 2 (4):123-40.
146. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
147. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):84-99.
148. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*. 2024;2(2):20-35.

149. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.
150. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
151. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
152. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine*. 2024;2(3):48-59.
153. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
154. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.
155. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
156. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.
157. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2 (3):111-117.